Aliases:This biomarker is also known as:
- translocator protein,
- benzodiazepine peripheral binding site,
- benzodiazapine receptor (peripheral),
- translocator protein (18kDa),
- peripheral-type benzodiazepine receptor,
- Peripheral-type benzodiazepine receptor,
- mitochondrial benzodiazepine receptor,
- Mitochondrial benzodiazepine receptor,
TSPO is a conserved protein found at the outer mitochondrial membrane. TSPO interacts with some benzodiazepines and isoquinoline carboxamides and has different affinities than its endogenous counterpart. TSPO is also involved in the transport of porphyrins and heme.
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
|QA State:||Under Review|
The TSPO gene is known to be over-expressed in highly aggressive tumors, especially those of the breast. Increasing levels of the TSPO protein are correlated with more advanced stages of breast cancer. Higher TSPO levels are found in estrogen receptor (ER)-negative breast tumors, compared with ER-positive tumors.
TSPO was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.
- The 18-kDa translocator protein (TSPO) disrupts mammary epithelial morphogenesis and promotes breast cancer cell migration.
- Translocator protein (TSPO) in breast cancer.
- Discovery and preliminary confirmation of novel early detection biomarkers for triple-negative breast cancer using preclinical plasma samples from the Women's Health Initiative observational study.
- Plasma biomarker profiles differ depending on breast cancer subtype but RANTES is consistently increased.